NasdaqGM:AGTC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Applied Genetic Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGTC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: AGTC's weekly volatility has decreased from 22% to 11% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

8.8%

AGTC

3.8%

US Biotechs

2.8%

US Market


1 Year Return

58.4%

AGTC

24.5%

US Biotechs

20.9%

US Market

Return vs Industry: AGTC exceeded the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: AGTC exceeded the US Market which returned 20.9% over the past year.


Shareholder returns

AGTCIndustryMarket
7 Day8.8%3.8%2.8%
30 Day-15.9%12.2%11.1%
90 Day-15.6%10.1%6.5%
1 Year58.4%58.4%26.6%24.5%23.6%20.9%
3 Year14.2%14.2%24.2%17.8%47.3%37.6%
5 Year-74.7%-74.7%13.7%5.9%94.3%72.9%

Long-Term Price Volatility Vs. Market

How volatile is Applied Genetic Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Applied Genetic Technologies undervalued compared to its fair value and its price relative to the market?

2x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGTC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGTC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGTC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AGTC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGTC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGTC is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Applied Genetic Technologies forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

11.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGTC is forecast to have no revenue next year.

High Growth Revenue: AGTC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGTC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Applied Genetic Technologies performed over the past 5 years?

-34.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGTC is currently unprofitable.

Growing Profit Margin: AGTC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 34.8% per year.

Accelerating Growth: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).


Return on Equity

High ROE: AGTC has a negative Return on Equity (-88.42%), as it is currently unprofitable.


Next Steps

Financial Health

How is Applied Genetic Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: AGTC's short term assets ($68.5M) exceed its short term liabilities ($13.0M).

Long Term Liabilities: AGTC's short term assets ($68.5M) exceed its long term liabilities ($16.4M).


Debt to Equity History and Analysis

Debt Level: AGTC's debt to equity ratio (17.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AGTC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGTC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AGTC has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 30.5% each year.


Next Steps

Dividend

What is Applied Genetic Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AGTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGTC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.3yrs

Average management tenure


CEO

Sue Washer (59 yo)

18.67yrs

Tenure

US$988,253

Compensation

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...


CEO Compensation Analysis

Compensation vs Market: Sue's total compensation ($USD988.25K) is above average for companies of similar size in the US market ($USD561.84K).

Compensation vs Earnings: Sue's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Susan Washer
President18.67yrsUS$988.25k0.11%
$ 123.3k
Mark Shearman
Chief Scientific Officer5.42yrsUS$814.32k0.053%
$ 59.8k
Stephen Potter
VP & Chief Business Officer5.83yrsUS$687.16k0.059%
$ 65.9k
Matthew Feinsod
Executive VP of Global Strategy & Development1.25yrsUS$815.37k0.26%
$ 286.7k
Nicholas Muzyczka
Co-Founder21.83yrsno datano data
Barry Byrne
Co-Founder21.83yrsno datano data
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datano datano data
Richard Samulski
Co-Founder21.83yrsno datano data
Terence Flotte
Co-Founder21.83yrsno datano data
William Sullivan
Chief Financial Officer3.25yrsUS$920.61kno data
Stacie Aarestad
Secretaryno datano datano data
Jonathan Sparks
Vice President of Legal Affairs5.08yrsno datano data

12.3yrs

Average Tenure

59yo

Average Age

Experienced Management: AGTC's management team is seasoned and experienced (12.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Susan Washer
President18.67yrsUS$988.25k0.11%
$ 123.3k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno datano datano data
Edward Hurwitz
Independent Director8yrsUS$72.19k0.11%
$ 119.2k
Anne VanLent
Independent Director4.25yrsUS$77.19kno data
Scott Koenig
Independent Chairman of the Board16.58yrsUS$104.19k0.13%
$ 148.6k
Ivana Magovcevic-Liebisch
Independent Director6.42yrsUS$80.19k0.012%
$ 13.0k
David Birch
Member of Ophthalmology Scientific Advisory Boardno datano datano data
William Aliski
Independent Director2.17yrsUS$67.19k0.033%
$ 36.9k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno datano datano data
James Rosen
Independent Director10.67yrsUS$65.19k0.0039%
$ 4.3k
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno datano datano data
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno datano datano data

8.0yrs

Average Tenure

59yo

Average Age

Experienced Board: AGTC's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.1%.


Top Shareholders

Company Information

Applied Genetic Technologies Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Applied Genetic Technologies Corporation
  • Ticker: AGTC
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$112.361m
  • Shares outstanding: 25.89m
  • Website: https://www.agtc.com

Number of Employees


Location

  • Applied Genetic Technologies Corporation
  • 14193 NW 119th Terrace
  • Suite 10
  • Alachua
  • Florida
  • 32615
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGTCNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDMar 2014
2GTDB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2014

Biography

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s advan...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/29 23:25
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.